臺灣博碩士論文加值系統

已有研究指出長期給予腎上腺素性乙型受體作用劑Isoproterenol可誘導心肌肥大的產生。另一種模式，自發性高血壓大鼠因長期自身的高血壓，也會導致心肌肥大和心衰竭。而一氧化氮合成酶抑制劑N-omega-nitro-L-arginine (L-NNA) 和ATP敏感型鉀離子通道阻斷劑 5-hydroxydecanoate (5-HD)則會讓心肌肥大的情形更加惡化。在本實驗擬探討第五型的磷酸二酯酶抑制劑KMUP-1和Sildenafil，在活體實驗中對於Isoproterenol所誘導心肌肥大或是自發性高血壓所產生的心肌肥大之影響，並觀察KMUP-1和Sildenafil對於cGMP和一氧化氮濃度以及在PKG、NOS、GSK-3?牷Bcalcineurin A 和ERK1/2之間的調控作用。
由實驗結果得知，每天給予大鼠皮下注射Isoproterenol (5毫克/公斤/天) 為期10天，可明顯地導致心肌肥大、心臟細胞受損及降低存活率。而給予自發性高血壓大鼠L-NNA (20毫克/升/天)，也會增加心肌的肥大情形和降低存活率。在給予Isoproterenol的前一個小時，腹腔注射KMUP-1 (0.5毫克/公斤/天) 和Sildenafil (0.7毫克/公斤/天)，在自發性高血壓大鼠也以腹腔注射KMUP-1 (0.5毫克/公斤/天)和Sildenafil (0.7毫克/公斤/天)。我們發現KMUP-1和Sildenafil可明顯地改善大鼠的存活率及減少心臟和體重的比率。KMUP-1和
Sildenafil會增加eNOS、PKG、GSK-3?猁漯穛{和cGMP及一氧化氮濃度，但是會降低iNOS、calcineurin A和ERK1/2的表現。然而，KMUP-1和Sildenafil所引起的作用會被L-NNA和5-HD所部份抑制。
從本實驗得知KMUP-1具有和Sildenafil相似的心臟保護作用，可防止Isoproterenol或是自發性高血壓所導致的心肌受損。KMUP-1可能是經由活化NO/cGMP/PKG的路徑來改善大鼠存活率及心臟功能，所以KMUP-1可能具有防止心肌肥大及治療心衰竭的功能。

It is known that chronic treatment of a ??-adrenergic agonist, isoproterenol, induced cardiac hypertrophy. Another model, spontaneously hypertensive rats (SHR) also developed chronic hypertension leading to cardiac hypertrophy and heart failure. When given of NOS inhibitor N-omega-nitro-L-arginine (L-NNA) or KATP channel blockor 5-hydroxydecanoate (5-HD), aggravated the response of cardiac hypertrophy. The present study investigated that the in vivo effects of KMUP-1 and sildenafil, phosphodiestrase-5 (PDE-5) inhibitors, on the hypertrophic responses of rat heart to isoproterenol and SHR, and the relation of the effects to the levels of myocardial cyclic guanosine monophosphate (cGMP) and nitric oxide, the activities of PKG, NOS, GSK3-???z?ncalcineurin A and ERK1/2.
The results showed that daily subcutaneous administration of isoproterenol for 10 days caused significantly cardiac hypertrophy, cell injury and decline in survival. Treatment of L-NNA (20 mg/l/day) in SHR also developed significantly cardiac hypertrophy and decline in survival. KMUP-1 (0.5 mg/kg/day) and sildenafil (0.7 mg/kg/day) were intraperitoneal injected, one hour before isoproterenol. KMUP-1 and sildenafil was also intraperitoneal injected to SHR. We found that both KMUP-1 and sildenafil significantly improved the survival rate and decreased the ratio of heart weight to body weight (HW/BW). Both KMUP-1 and sildenafil increased the expression of eNOS, PKG and GSK-3??, and the production of NO and cGMP, but suppressed the expression of iNOS, calcineurin A and ERK1/2. However these effects of KMUP-1 and sildenafil were partially reversed by treatment of L-NNA and 5-HD.
These present study indicated that KMUP-1 similar to sildenafil has a cardioprotective effect against isoproterenol- and spontaneously hypertension-induced myocardial cell injury. KMUP-1 may through the activation NO/cGMP/PKG-1 pathway and then to improve survival rate and cardiac function, suggesting that it may have great potential in the prevention of cardiac hypertrophy and heart failure.

1.中文摘要 ------1
2.英文摘要 ------3
3.縮寫表 --------5
4.緒論 ----------7
5.研究材料 ------14
6.研究方法 ------22
7.實驗結果 ------31
8.討論 ----------44
9.參考文獻 ------52
10.附圖與附表 ---62

Abbate A, Scarpa S, Santini D, Palleiro J, Vasaturo F, Miller J, Morales C, Vetrovec GW, Baldi A. (2005) Myocardial expression of survivin, an apoptosis inhibitor, in aging and heart failure. An experimental study in the spontaneously hypertensive rat. Biochem J. 314:115–21.
Antos CL, McKinsey TA, Frey N, Kutschke W, McAnally J, Shelton JM, Richardson JA, Hill JA, Olson EN. (2002) Activated glycogen synthase-3 beta suppresses cardiac hypertrophy in vivo. Proc Natl Acad Sci U S A. 99:907-12.
Badenhorst D, Veliotes D, Maseko M, Tsotetsi OJ, Brooksbank R, Naidoo A, Woodiwiss AJ, Norton GR. (2003) Beta-adrenergic activation initiates chamber dilatation in concentric hypertrophy. Hypertension. 41:499-504.
Bartunek J, Weinberg EO, Tajima M, Rohrbach S, Katz SE, Douglas PS, Lorell BH. (2000) Chronic N(G)-nitro-L-arginine methyl ester-induced hypertension : novel molecular adaptation to systolic load in absence of hypertrophy. Circulation. 101:423-9.
Bernatova I, Pechanova O, Pelouch V, Simko F. (2000) Regression of chronic L -NAME-treatment-induced left ventricular hypertrophy: effect of captopril. J Mol Cell Cardiol. 32:177-85.
Bogoyevitch MA, Andersson MB, Gillespie-Brown J, Clerk A, Glennon PE, Fuller SJ, Sugden PH. (1996) Adrenergic receptor stimulation of the mitogen-activated protein kinase cascade and cardiac hypertrophy. Biochem J. 314 :115-21.
Bohm M, Ettelbruck S, Flesch M, van Gilst WH, Knorr A, Maack C, Pinto YM, Paul M, Teisman AC, Zolk O. (1998) Beta-adrenergic signal transduction following carvedilol treatment in hypertensive cardiac hypertrophy. Cardiovasc Res. 40:146-55.
Brookes PS, Zhang J, Dai L, Zhou F, Parks DA, Darley-Usmar VM, Anderson PG. (2001) Increased sensitivity of mitochondrial respiration to inhibition by nitric oxide in cardiac hypertrophy. J Mol Cell Cardiol. 33:69-82.
Carson P. (2001) beta-blocker therapy in heart failure. Cardiol Clin. 19:267-78.
Dai L, Brookes PS, Darley-Usmar VM, Anderson PG. (2001) Bioenergetics in cardiac hypertrophy: mitochondrial respiration as a pathological target of NO*. Am J Physiol Heart Circ Physiol. 281:H2261-9.
de Andrade Zorzi RL, Meirelles Pereira LM, Mandarim-de-Lacerda CA. (2002) Beneficial effect of enalapril in spontaneously hypertensive rats cardiac remodeling with nitric oxide synthesis blockade. J Cell Mol Med. 6:599-608.
de Oliveira CF, Cintra KA, Teixeira SA, De Luca IM, Antunes E, De Nucci G. (2000) Development of cardiomyocyte hypotrophy in rats under prolonged treatment with a low dose of a nitric oxide synthesis inhibitor. Eur J Pharmacol. 391:121-6.
Doggrell SA, Brown L. (1998) Rat models of hypertension, cardiac hypertrophy and failure. Cardiovasc Res. 39:89–105.
Dorn GW 2nd, Force T. (2005) Protein kinase cascades in the regulation of c ardiac hypertrophy. J Clin Invest. 115:527-37.
Dorn GW 2nd. (2005) Physiologic growth and pathologic genes in cardiac development and cardiomyopathy. Trends Cardiovasc Med. 15:185-9.
Dudnakova TV, Lakomkin VL, Tsyplenkova VG, Shekhonin BV, Shirinskii VP, Kapel''ko VI. Dudnakova TV, Lakomkin VL, Tsyplenkova VG, Shekhonin BV, Shirinskii VP, Kapel''ko VI. (2002) .Isoproterenol induced changes of protein expression and myocardial ultrastructure Kardiologiia. 42:57-63.
Frey N, McKinsey TA, Olson EN. (2000) Decoding calcium signals involved in cardiac growth and function. Nat Med. 6:1221-7.
Gealekman O, Abassi Z, Rubinstein I, Winaver J, Binah O. (2002) Role of myocardial inducible nitric oxide synthase in contractile dysfunction and beta-adrenergic hyporesponsiveness in rats with experimental volume-overload heart failure. Circulation. 15:236-43.
Gupta S, Young D, Sen S. (2005) Inhibition of NF-kappaB induces regression of cardiac hypertrophy, independent of blood pressure control, in spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol. 289:H20-9.
Hardt SE, Sadoshima J. (2002) Glycogen synthase kinase-3beta: a novel regulator of cardiac hypertrophy and development. Circ Res. 90:1055-63.
Hassan MA, Ketat AF. (2005) Sildenafil citrate increases myocardial cGMP content in rat heart, decreases its hypertrophic response to isoproterenol and decreases myocardial leak of creatine kinase and troponin T. BMC Pharmacol. 5:10
Izumo S, Shioi T. (1998) Cardiac transgenic and gene-targeted mice as models of cardiac hypertrophy and failure: a problem of (new) riches. J Card Fail. 4:263-70.
Jin X, Xia L, Wang LS, Shi JZ, Zheng Y, Chen WL, Zhang L, Liu ZG, Chen GQ, Fang NY. (2006) Differential protein expression in hypertrophic heart with and without hypertension in spontaneously hypertensive rats. Proteomics. 6:1948-56.
Kelly RA, Balligand JL, Smith TW. (1996) Nitric oxide and cardiac function. Circ Res . 79:363-80.
Kitagawa Y, Yamashita D, Ito H, Takaki M. (2004) Reversible effects of isoproterenol-induced hypertrophy on in situ left ventricular function in rat hearts. Am J Physiol Heart Circ Physiol. 87:H277-85.
Kukreja RC, Ockaili R, Salloum F, Yin C, Hawkins J, Das A, Xi L. (2004) Cardioprotection with phosphodiesterase-5 inhibition--a novel preconditioning strategy. J Mol Cell Cardiol. 36:165-73.
Kukreja RC, Salloum F, Das A, Ockaili R, Yin C, Bremer YA, Fisher PW, Wittkamp M, Hawkins J, Chou E, Kukreja AK, Wang X, Marwaha VR, Xi L. (2005) Pharmacological preconditioning with sildenafil: Basic mechanisms and clinical implications. Vascul Pharmacol. 42:219-32.
Leenen FH, White R, Yuan B. (2001) Isoproterenol-induced cardiac hypertrophy: role of circulatory versus cardiac renin-angiotensin system. Am J Physiol Heart Circ Physiol. 281:H2410-6.
Liao Y, Asakura M, Takashima S, Ogai A, Asano Y, Shintani Y, Minamino T, Asanuma H, Sanada S, Kim J, Kitamura S, Tomoike H, Hori M, Kitakaze M. (2004) Celiprolol, a vasodilatory beta-blocker, inhibits pressure overload-induced cardiac hypertrophy and prevents the transition to heart failure via nitric oxide-dependent mechanisms in mice. Circulation. 110:692-9.
Lin RJ, Wu BN, Lo YC, Shen KP, Lin YT, Huang CH, Chen IJ. (2002) KMUP-1 relaxes rabbit corpus cavernosum smooth muscle in vitro and in vivo: involvement of cyclic GMP and K(+) channels. Br J Pharmacol. 135:1159-66.
Lorell BH, Carabello BA. (2000) Left ventricular hypertrophy: pathogenesis, detection, and prognosis. Circulation.102:470-9.
Massion PB, Pelat M, Belge C, Balligand JL. (2005) Regulation of the mammalian heart function by nitric oxide. Comp Biochem Physiol A Mol Integr Physiol. 142:144-50.
Mendelsohn ME. (2005) Viagra: now mending hearts. Nat Med. 11:214-22.
Molkentin JD, Lu JR, Antos CL, Markham B, Richardson J, Robbins J, Grant SR, Olson EN. (1998) A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell. 93:215-28.
Nadal-Ginard B, Kajstura J, Leri A, Anversa P. (2003) Myocyte death, growth, and regeneration in cardiac hypertrophy and failure. Circ Res. 92:139-50.
Nishikimi T, Maeda N, Matsuoka H. (2006) The role of natriuretic peptides in cardioprotection. Cardiovasc Res. 69:318-28
Nishimura RA, Ommen SR, Tajik AJ. (2003) Cardiology patient page. Hypertrophic cardiomyopathy: a patient perspective. Circulation. 108: 133-135.
Obata K, Nagata K, Iwase M, Odashima M, Nagasaka T, Izawa H, Murohara T, Yamada Y, Yokota M. (2005) Overexpression of calmodulin induces cardiac hypertrophy by a calcineurin-dependent pathway. Biochem Biophys Res Commun. 338:1299-305.
Ockaili R, Salloum F, Hawkins J, Kukreja RC. (2002) Sildenafil (Viagra) induces powerful cardioprotective effect via opening of mitochondrial K(ATP) channels in rabbits. Am J Physiol Heart Circ Physiol. 283:H1263-9.
Olson EN, Molkentin JD. (1999) Prevention of cardiac hypertrophy by calcineurin inhibition: hope or hype? Circ Res. 84:623-32.
Olzinski AR, McCafferty TA, Zhao SQ, Behm DJ, Eybye ME, Maniscalco K, Bentley R, Frazier KS, Milliner CM, Mirabile RC, Coatney RW, Willette RN. (2005) Hypertensive target organ damage is attenuated by a p38 MAPK inhibitor: role of systemic blood pressure and endothelial protection. Cardiovasc Res. 66:170-8.
Riado SR, Zanesco A, Barker LA, De Luca IM, Antunes E, De Nucci G. (1999) Long-term nitric oxide inhibition and chronotropic responses in rat isolated right atria. Hypertension. 34:802-7.
Schulz RA, Yutzey KE. (2004) Calcineurin signaling and NFAT activation in cardiovascular and skeletal muscle development. Dev Biol. 266:1-16.
Song XJ, Wang ZB, Gan Q, Walters ET. (2006) cAMP and cGMP contribute to sensory neuron hyperexcitability and hyperalgesia in rats with dorsal root ganglia compression. J Neurophysiol. 95:479-92.
Swynghedauw B. (1999) Molecular mechanisms of myocardial remodeling. Physiol Rev. 79:215-62.
Takimoto E, Champion HC, Li M, Belardi D, Ren S, Rodriguez ER, Bedja D, Gabrielson KL, Wang Y, Kass DA. (2005) Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med.11:115-6.
Tarone G, Lembo G. (2003) Molecular interplay between mechanical and humoral signalling in cardiac hypertrophy. Trends Mol Med. 9:376-82.
Wilkins BJ, Molkentin JD. (2004) Calcium-calcineurin signaling in the regulation of cardiac hypertrophy. Biochem Biophys Res Commun. 322:1178-91.
Wu BN, Lin RJ, Lin CY, Shen KP, Chiang LC, Chen IJ. (2001) A xanthine-based KMUP-1 with cyclic GMP enhancing and K(+) channels opening activities in rat aortic smooth muscle. Br J Pharmacol. 134:265-74.
Wu BN, Lin RJ, Lo YC, Shen KP, Wang CC, Lin YT, Chen IJ. (2004) KMUP-1, a xanthine derivative, induces relaxation of guinea-pig isolated trachea: the role of the epithelium, cyclic nucleotides and K+ channels. Br J Pharmacol. 142:1105-14.
Yu CM, Fung PC, Chan G, Lai KW, Wang Q, Lau CP. (2001) Plasma nitric oxide level in heart failure secondary to left ventricular diastolic dysfunction. Am J Cardiol. 88:867-70.